Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

20.41 -0.52 (-2.48%)
Streaming Delayed Price Updated: 12:04 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Castle Biosciences, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Castle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry
From Castle Biosciences Inc.
Via Business Wire
TissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Inc. (NASDAQ: CSTL) Leading the Way in Friday Trading Based on Percentage Gain
Via Investor Brand Network
Integrating Drug-Drug Interactions and Lifestyle Factors with Drug-Gene Interactions Provided by Castle Biosciences’ IDgenetix® Test Significantly Impacted the Number of Drug Recommendations for Patients with Moderate to Severe Depression
From Castle Biosciences Inc.
Via Business Wire
TissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barrett’s Esophagus
From Castle Biosciences Inc
Via Business Wire
Castle Biosciences to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences Inc.
Via Business Wire
New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Reports Second Quarter 2023 Results
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth Conference
From Castle Biosciences Inc.
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Relmada, DoubleVerify, and Castle and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Castle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Host Second Annual Castle Cares Charity Walk
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive Year
From Castle Biosciences Inc.
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Castle, Coinbase, Arrival, and BeiGene and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Advance Auto Parts, EPAM, and Castle and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Castle Biosciences to Present New DecisionDx®-SCC and DecisionDx®-Melanoma Data at the American Head & Neck Society’s (AHNS) 11th International Conference on Head and Neck Cancer
From Castle Biosciences Inc.
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Advance Auto Parts, EPAM, and Castle Biosciences and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating EPAM, Castle, BeiGene and Fox and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Study Data from Castle Biosciences’ Collaboration with the National Cancer Institute’s SEER Program Registries Published in JCO Precision Oncology
From Castle Biosciences Inc.
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Comerica, Advance Auto Parts, EPAM, and Castle and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences Inc.
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Texas Capital, EPAM, and Castle and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Continues Investigation of Shareholder Claims Against Castle BioSciences, Inc. (CSTL)
From Kirby McInerney LLP
Via Business Wire
CASTLE ALERT: Bragar Eagel & Squire, P.C. is Investigating Castle Biosciences, Inc. on Behalf of Castle Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Castle Biosciences Presents New Data Demonstrating the Ability of DecisionDx®-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging
From Castle Biosciences Inc.
Via Business Wire
Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Castle Biosciences, Inc. (CSTL)
From Kirby McInerney LLP
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Castle Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Castle Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.